---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-24-006472"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:41:56.157037+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix cuts 23 employees, closes Mass. facility; shareholders approve reverse stock split

## Summary
- Workforce reduction of 23 FTEs and decommissioning of Advanced Development Center in Mass. by June 7, 2024.
- No material charge expected for restructuring; impairment amount not yet determinable.
- Shareholders (61.6% of shares) elected 8 directors, ratified EisnerAmper as auditor.
- Approved reverse stock split of 1:2 to 1:50, board to set exact ratio within one year.
- Approved repricing of up to 93.4M warrants issued Aug-Dec 2023.

## SEC filing metadata
- accession: 0001999371-24-006472
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 2.06, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/0001999371-24-006472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/tnpx_8k-052224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-24-006472
- JSON: https://secwatch.observer/filing/0001999371-24-006472.json
- Plain text: https://secwatch.observer/filing/0001999371-24-006472.txt

## Key facts
- Restructurings & Charges
  Tonix Pharmaceuticals Holding Corp. announced a restructuring affecting Advanced Development Center ("ADC") in Massachusetts (23 full-time employees).
  - Type: restructuring
  - Affected area: Advanced Development Center ("ADC") in Massachusetts
  - Headcount: 23 full-time employees
  source text: Tonix Pharmaceuticals Holding Corp. (the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Company’s capital and human resources with its previously announced strategic prioritization of its TonmyaTM (TNX-102 SL cyclobenzaprine HCl sublingual tablet) product candidate for the management of fibromyalgia
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/0001999371-24-006472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.